Concepedia

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China

Shuyan Gu, Yiming Mu, Suodi Zhai, Yuhang Zeng, Xuemei Zhen, Hengjin Dong

PLoS ONE · 2016 · 33 citations · 75 references

DOIFull text

Open access

Abstract

Dapagliflozin is dominant compared with acarbose as monotherapy for Chinese T2DM patients, with a little QALY gain and lower costs. Dapagliflozin offers a well-tolerated and cost-effective alternative medication for treatment-naive patients in China, and may have a direct impact in reducing the disease burden of T2DM.

References

75

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

The Lancet · 1998 · 19.9K citations

, , +9

International Diabetes Federation 2017

Ann M. Carracher, Payal H. Marathe, Kelly L. Close · Journal of Diabetes · 2018 · 13.5K citations · Full text

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

Stephen S Lim, Theo Vos, Abraham D Flaxman et al. · The Lancet · 2012 · 11.9K citations · Full text

, , +17

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Irene Stratton · BMJ · 2000 · 8.9K citations · Full text

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

R. C. Turner, Charles Fox, Matthews et al. · The Lancet · 1998 · 8.4K citations

, , +10